PL2988756T5 - Formulacja środka kontrastowego i powiązany sposób jego wytwarzania - Google Patents

Formulacja środka kontrastowego i powiązany sposób jego wytwarzania

Info

Publication number
PL2988756T5
PL2988756T5 PL14723750.7T PL14723750T PL2988756T5 PL 2988756 T5 PL2988756 T5 PL 2988756T5 PL 14723750 T PL14723750 T PL 14723750T PL 2988756 T5 PL2988756 T5 PL 2988756T5
Authority
PL
Poland
Prior art keywords
contrast medium
medium formulation
related preparation
preparation
formulation
Prior art date
Application number
PL14723750.7T
Other languages
English (en)
Polish (pl)
Other versions
PL2988756T3 (pl
Inventor
Christelle Medina
Monique SABATOU
Anne PETIT
Marc Port
Original Assignee
Guerbet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48856855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2988756(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guerbet filed Critical Guerbet
Publication of PL2988756T3 publication Critical patent/PL2988756T3/pl
Publication of PL2988756T5 publication Critical patent/PL2988756T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
PL14723750.7T 2013-04-26 2014-04-28 Formulacja środka kontrastowego i powiązany sposób jego wytwarzania PL2988756T5 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353883 2013-04-26
PCT/EP2014/058617 WO2014174120A1 (fr) 2013-04-26 2014-04-28 Formulation de produit de contraste et son procede de preparation associe

Publications (2)

Publication Number Publication Date
PL2988756T3 PL2988756T3 (pl) 2017-08-31
PL2988756T5 true PL2988756T5 (pl) 2022-09-26

Family

ID=48856855

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14723750.7T PL2988756T5 (pl) 2013-04-26 2014-04-28 Formulacja środka kontrastowego i powiązany sposób jego wytwarzania

Country Status (14)

Country Link
US (1) US10918743B2 (enExample)
EP (1) EP2988756B2 (enExample)
JP (1) JP6608805B2 (enExample)
KR (1) KR102231121B1 (enExample)
CN (2) CN105142649A (enExample)
BR (1) BR112015026473B1 (enExample)
CA (1) CA2909919C (enExample)
DK (1) DK2988756T4 (enExample)
ES (1) ES2626582T5 (enExample)
HR (1) HRP20170874T4 (enExample)
HU (1) HUE033219T2 (enExample)
PL (1) PL2988756T5 (enExample)
PT (1) PT2988756T (enExample)
WO (1) WO2014174120A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
FR3039767B1 (fr) 2015-08-04 2017-09-08 Guerbet Sa Composition destinee a vectoriser un agent anticancereux
GB201610738D0 (en) 2016-06-20 2016-08-03 Ge Healthcare As Chelate compounds
KR102464647B1 (ko) 2016-11-28 2022-11-08 바이엘 파마 악티엔게젤샤프트 자기 공명 영상화에 사용하기 위한 높은 이완도 가돌리늄 킬레이트 화합물
CA3048104A1 (en) 2016-12-21 2018-06-28 Ge Healthcare As Tetraazabicyclo-macrocycle based manganese chelate compounds suitable as mri imaging agents
CN111712477B (zh) 2017-12-20 2024-02-02 通用电气公司 阴离子螯合物化合物
JP7558146B2 (ja) 2018-08-06 2024-09-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニ Ｐｃｔａベースの造影剤
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof
US11426470B2 (en) 2019-01-17 2022-08-30 Guerbet Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched PCTA and synthesis method
FR3091872B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de synthese
FR3091873B1 (fr) * 2019-01-17 2020-12-25 Guerbet Sa Complexe de gadolinium et d’un ligand chelateur derive de pcta diastereoisomeriquement enrichi et procede de preparation et de purification
US11370804B2 (en) 2019-01-17 2022-06-28 Guerbet Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
KR20230041007A (ko) * 2020-07-17 2023-03-23 게르브 Pcta로부터 유도된 킬레이팅 리간드의 제조 방법
US12409239B2 (en) 2021-06-25 2025-09-09 Beacon Mri Ltd Particles for use in hyperpolarization

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3854717T3 (de) 1987-06-30 1999-04-15 Mallinckrodt, Inc. (N.D.Ges.Des Staates Delaware), St. Louis, Mo. Verfahren zur erhöhung der sicherheit von metall-ligandchelaten als röntgenstrahlen-kontrastmittel.
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
GB9001245D0 (en) * 1990-01-19 1990-03-21 Salutar Inc Compounds
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2039399C (en) * 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
DE4115789A1 (de) 1991-05-10 1992-11-12 Schering Ag Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
ZA929575B (en) 1991-12-10 1994-06-10 Dow Chemical Co Bicyclopolyazamacrocyclocarboxyclic acid complexes,their conjugates,processes for their preparation,and use as contrast agents
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
DE19719033C1 (de) 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6559330B1 (en) 1999-09-09 2003-05-06 Schering Aktiengesellschaft Calcium complex of [[(4r)-4-[bis{carboxy-.kappa.o)methyl]amino-.kappa.n]-6,9-bis[(carboxy.kappa.o)methyl]-1-[(4,4-diphenylcyclohexyl)oxy]-1-hydroxy-2-oxa-6,9-diaza-1-phosphaundecan-11-ylic-acid-.kappa.n6,.kappa.n9,.kappa.011]1-oxidato(6-)]-, hexahydrogen, its salts, pharmaceutical agents that contain these complexes, their use in treatment and as additives in diagnosis, as well as processes for the production of the complexes and agents
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
US20090208421A1 (en) * 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2927539B1 (fr) * 2008-02-19 2010-07-30 Guerbet Sa Procede de preparation d'une formulation pharmaceutique d'agents de contraste.
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
EP2554167A1 (en) * 2011-08-02 2013-02-06 Bracco Imaging S.p.A New use of l-histidine and derivatives thereof

Also Published As

Publication number Publication date
KR20160002821A (ko) 2016-01-08
HRP20170874T4 (hr) 2022-09-02
BR112015026473A2 (pt) 2017-07-25
US10918743B2 (en) 2021-02-16
CN116173247A (zh) 2023-05-30
BR112015026473B1 (pt) 2020-12-01
EP2988756B1 (fr) 2017-03-08
EP2988756B2 (fr) 2022-05-18
JP2016521275A (ja) 2016-07-21
KR102231121B1 (ko) 2021-03-23
HRP20170874T1 (hr) 2017-09-22
CA2909919C (fr) 2022-07-12
DK2988756T4 (da) 2022-08-08
CN105142649A (zh) 2015-12-09
WO2014174120A1 (fr) 2014-10-30
US20160101196A1 (en) 2016-04-14
DK2988756T3 (en) 2017-06-26
JP6608805B2 (ja) 2019-11-20
PT2988756T (pt) 2017-05-08
CA2909919A1 (fr) 2014-10-30
HUE033219T2 (en) 2017-11-28
PL2988756T3 (pl) 2017-08-31
EP2988756A1 (fr) 2016-03-02
ES2626582T5 (es) 2022-10-07
ES2626582T3 (es) 2017-07-25

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
PL2988756T5 (pl) Formulacja środka kontrastowego i powiązany sposób jego wytwarzania
GB2521022B (en) Compositions and methods
IL244081A0 (en) Preparations and methods for modulating RNA
SMT201900635T1 (it) Composizioni e metodi di attivazione della segnalazione dipendente dallo "stimolatore di geni interferone"
IL243425A0 (en) Formulations and methods based on antibodies
EP2999999A4 (en) Food preparation apparatus and methods
IL265876A (en) Preparations that include 15-ohepa and methods of using them
GB201308072D0 (en) Compositions and methods
GB201312189D0 (en) New cleaning formulation and method
GB201306633D0 (en) Biaising circuitry and method thereof
GB201305414D0 (en) Method and composition
SG11201601130YA (en) Film-forming composition and film-forming method using same
PL3084506T3 (pl) Endoskop i sposób jego użycia
GB201305813D0 (en) Compositions and methods
PL3048883T3 (pl) Kompozycja pestycydowa i sposób
AP2016009262A0 (en) Siliceous composition and method for obtaining same
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB2515335B (en) Foodstuff and foodstuff preparation method
GB201311234D0 (en) Rotary Coupling and Method
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
AU2013900810A0 (en) Game and Method
GB201310349D0 (en) Composition and method of use thereof